Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 23Terminated 4Unknown 3Withdrawn 2Recruiting 2Not yet recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Anemia, Refractory, with Excess of Blasts 5Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Graft vs Host Disease 3Recurrence 2Neuroblastoma 2Neoplasms 2Neoplasm, Residual 2Myelodysplastic-Myeloproliferative Diseases 2Multiple Myeloma 2Lymphoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Leukemia 2Hodgkin Disease 2beta-Thalassemia 1Primary Myelofibrosis 1Neurofibromatosis 1 1Metabolic Diseases 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Busulfan × Clear all
NCT06802315 2025-06-25

BMT-13

University of Illinois at Chicago

Phase 2 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT02859402 2022-08-18

RRTCLAlloSCT

Keimyung University Dongsan Medical Center

Phase 2 Recruiting
34 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡